Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II combined systemic and intrathecal chemotherapy in HER2-negative breast cancer with leptomeningeal spread
2009-014300-55Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, ifosfamide and liposomal cytarabine in breast cancer and Carcinomatous Meningitis (CM), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Neurologic progression rate at 1 year. Started Dec 2009; status: terminated.
02
Drugs
methotrexateifosfamideliposomal cytarabine
03
Conditions
breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on 2009-014300-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014300-55.